Bevacizumab Demonstrates Prolonged Disease Stabilization in Patients with Heavily Pretreated Metastatic Renal Cell Carcinoma: A Case Series and Review of the Literature

Table 1

Patient characteristics and responses to treatments.

Patient ID	Age	Gender	Prior Treatment	Responses to Prior Treatment	Bevacizumab best response and duration of response
A	73	M	Sunitinib	SD for 54 weeks	SD for 48 weeks
			Temsirolimus	PD after 3 cycles (3 months)
B	76	M	IL-2	PR after 12 weeks	SD for 72 weeks*
			Sorafenib	PR for 24 weeks
			Sunitinib	PR for 54 weeks
			Temsirolimus	AE after 12 weeks
C	56	M	IL-2	PD after 8 weeks	SD for >24 weeks*
			Sunitinib	SD for 24 weeks
			Temsirolimus	AE after 12 weeks
D	58	F	IL-2	PD after 12 weeks	SD for 48 weeks
			Sunitinib	SD for 84 weeks
			Sorafenib	SD for 36 weeks
			Temsirolimus	PD after 12 weeks

SD: Stable disease, PD: Progression of disease, PR: Partial response, AE: Adverse event.
*Patient still on therapy at the time of publication.